Bolt Biotherapeutics
BOLT
44 hedge funds and large institutions have $26.8M invested in Bolt Biotherapeutics in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 14 increasing their positions, 12 reducing their positions, and 13 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 12
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.82% less ownership
Funds ownership: 3.56% → 2.73% (-0.82%)
21% less funds holding
Funds holding: 56 → 44 (-12)
30% less capital invested
Capital invested by funds: $38.5M → $26.8M (-$11.7M)
92% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
+$754K |
| 2 |
Goldman Sachs
New York
|
+$371K |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$274K |
| 4 |
Millennium Management
New York
|
+$171K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$102K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$5.48M |
| 2 |
SCM
Suvretta Capital Management
New York
|
-$3.96M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$789K |
| 4 |
BlackRock
New York
|
-$233K |
| 5 |
CCM
CAAS Capital Management
New York
|
-$173K |
BOLT Hedge Fund Activity: Q4 2022 in Review
44 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q4 2022, worth a combined $26.8M — down 30% from $38.5M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of BOLT and 1 opened new positions — a net loss of 12 holders — while 12 trimmed existing stakes and 14 added.
The largest buyer was Newtyn Management, adding an estimated $754K. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $5.48M sold.
- 44 institutional investors held Bolt Biotherapeutics (BOLT) as of Q4 2022, down from 56 in Q3 2022.
- Funds reported $26.8M of Bolt Biotherapeutics stock for Q4 2022, down 30% quarter-over-quarter.
- 1 fund opened new Bolt Biotherapeutics positions in Q4 2022 and 13 closed out, a net change of -12 holders.
- The largest Bolt Biotherapeutics buyer in Q4 2022 was Newtyn Management, an estimated $754K added.
- The largest Bolt Biotherapeutics seller in Q4 2022 was Novo Holdings A/S, an estimated $5.48M sold.
Based on aggregated 13F filings for Q4 2022.